病例分享:因咳嗽、呼吸困难入院的患者为何突发肌腱病变?意外受伤吗?

2018-03-28 山西医科大学第一医院 樊海霞 晋中市第一人民医院 张敏恒 李神经会诊中心群

近期,本文作者在临床上遇到一个特殊情况:68岁男性患者因肺间质纤维化合并感染入院治疗,入院时病情虽危重,但经治疗逐渐好转。

推荐语

近期,本文作者在临床上遇到一个特殊情况:68岁男性患者因肺间质纤维化合并感染入院治疗,入院时病情虽危重,但经治疗逐渐好转。

然而,事情并不是到这里就迎来了happy ending,患者在入院第8天时,自述小腿痛,进行了多种检查后,考虑肌腱病变。

患者是意外受伤了吗?不少人都认为剧烈运动才可能损伤肌腱,其实服用某些药物也是危险因素,而且没有患者可以完全免于此风险、跟腱断裂又可能在无任何警示的情况下发生……所以,我们应如何分辨与处理临床上的类似问题?哪类人最易中枪?他们的预后是否乐观?

患者男性,68岁,主因「间断咳嗽、咳痰、呼吸困难2月,加重2天」入院。

既往:冠心病史3年,房颤病史3年(胺碘酮200mg/日),吸烟40余年,7支/日,戒烟1月,余无特殊。

入院查体:T36.8℃,P78次/分,R19次/分,Bp134/72mmHg,神志清楚,球结膜无水肿,颈静脉无怒张,双肺呼吸音弱,未闻及干湿啰音,心率78次/分,律齐,各瓣膜听诊区未闻及病理性杂音,腹软,肝脾肋下未及,无压痛反跳痛,双下肢无水肿。

辅助检查:

血气分析(我院):

PH 7.47,PCO2 32.2mmHg,PO2 40mmHg;

胸部CT(外院)示:

1、右肺上叶、下叶,左肺上叶多发大片磨玻璃影;

2、双肺下叶多发索条影。肺功能(1年前,我院)示:通气储备:89.19%,通气功能呈轻度限制性改变,FEV1占93.3%预计值,FEV1/FVC:74.49%;肺总量轻度减低占77.4%预计值,残气量正常;弥散功能中度减低占44.6%预计值。

临床考虑为:

1、肺间质纤维化合并感染I型呼吸衰竭

2、冠状动脉粥样硬化性心脏病

3、心律失常、心房颤动等。

入院时病情危重,给予无创呼吸机辅助呼吸,同时给予「亚胺培南西司他汀钠、莫西沙星、甲泼尼龙琥珀酸钠」抗感染,三天后抗生素降级,给予「头孢西丁、左氧氟沙星」降阶梯治疗,病情逐渐好转。

然而,患者在入院第8天时,自述小腿痛,查体未见水肿,有触痛,予以化验及b超检查,化验回报:肌酸激酶:3040U/L;D-二聚体:700.00ng/ml等,下肢彩超:双下肢动脉硬化伴小斑块形成;左侧腓静脉中段及上段血栓形成;左小腿肌间静脉血栓形成;双侧小腿腓肠肌肌腱水肿增粗——考虑肌腱病变。

那么问题来了,患者因何导致了双侧小腿腓肠肌肌腱水肿增粗伴肌酶升高呢?

通过查阅文献及请教主任,考虑为喹诺酮相关肌腱炎,遂停用喹诺酮类药物,嘱患者静养等对症处理,目前仍在随访中。

近年来,氟喹酮类药物的安全问题受到了越来越多国家的关注,其中严重不良事件就包括肌腱炎和腱断裂。目前的数据显示,喹诺酮类药物诱发的肌腱病发生率0.14~0.4%,虽然发生率低,但是其后果严重,故而所有氟喹诺酮类药物在产品标签中都有「黑匣子」警告——FDA最高级别警告。

所以,我们急需系统地认识和了解一下喹诺酮相关的肌腱炎及肌腱断裂——它有哪些比较显著的临床特点?出现此类情况的常见风险因素有哪些?能否治疗?预后是否乐观?

临床特点

1、通常累及负重肌腱,跟腱是最常见的受累部,其他部位如肩袖、肱二头肌、手、四头肌等亦可受累。一项研究表明,约90%喹诺酮相关性肌腱炎和肌腱断裂累及跟腱,并在高达50%的病例可见双侧跟腱同时受累。

2、急性起病,主要表现为跟腱处水肿、压痛和肿胀,步行时疼痛加重,程度剧烈,其严重程度可能与水肿程度相关。

3、多数肌腱疾病发生在开始使用喹诺酮治疗的9~13天内,大部分事件发生在第一个月以内,但是长达18个月内仍然可能发生。

4、不同种类的喹诺酮药物引起的临床表现并无明显差别。

5、跟腱断裂可能在无任何警示的情况下发生。

易感因素

最常见风险因素包括:

1、年龄大于60岁

2、类固醇治疗

3、肾脏疾病或移植

4、既往肌腱病史

其他报道的危险因素包括:

先前或目前从事体育活动

缺镁

血液透析

痛风

免疫抑制治疗

部分疾病,如糖尿病,类风湿性关节炎、高脂血症、哮喘,慢性阻塞性肺疾病,慢性支气管炎、溃疡性结肠炎克罗恩病、甲状旁腺功能亢进、器官移植史等

低肌肉量

肥胖等

注意:对于以上有风险因素的患者,临床医生需警惕喹诺酮肌腱病的发生,但是没有患者可以完全免于此风险。

临床处理

若在使用药物期间发生症状,可选择停药或换用其他对跟腱影响较小的药物。

根据严重程度,可采用非手术或手术干预。非手术策略适用于大多数患者,包括使用镇痛药、理疗、石膏和/或固定等,严重患者则需考虑手术。

预后相关

1、从目前的数据显示,一般预后良好。在一项包括421例喹诺酮相关肌腱病的回顾性研究发现,66%的患者恢复良好(24%未知),恢复时间大概是停药后15~30天,部分患者恢复时间较长。在极少数情况下,症状可在停药后持续6个月以上。

2、据估计,大约10%的患者发生长期并发症(如肿胀、瘀伤、行走困难、屈曲能力下降、活动受限和疼痛等)。

从目前的数据显示,左氧氟沙星及氧氟沙星发生肌腱病的病例报告最多,在老年人并且合并多种易感因素时,需要考虑到该副作用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=307067, encodeId=ea8b30e06741, content=还有这样的副作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/10/4591d13f0d10510467d5b87f98bc17f8.jpg, createdBy=aad42328838, createdName=成长中, createdTime=Wed Apr 18 23:31:41 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301254, encodeId=96e03012548f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 30 20:22:18 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281862, encodeId=d1311281862ec, content=<a href='/topic/show?id=21753963364' target=_blank style='color:#2F92EE;'>#呼吸困难#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39633, encryptionId=21753963364, topicName=呼吸困难)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512606, encodeId=3dbf1512606d1, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300734, encodeId=5e00300e34a5, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Mar 29 06:57:44 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300642, encodeId=14e73006425c, content=药物并发症.禁忌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:34 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300641, encodeId=3b72300641cb, content=药物并发症, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:21 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-04-18 成长中

    还有这样的副作用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=307067, encodeId=ea8b30e06741, content=还有这样的副作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/10/4591d13f0d10510467d5b87f98bc17f8.jpg, createdBy=aad42328838, createdName=成长中, createdTime=Wed Apr 18 23:31:41 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301254, encodeId=96e03012548f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 30 20:22:18 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281862, encodeId=d1311281862ec, content=<a href='/topic/show?id=21753963364' target=_blank style='color:#2F92EE;'>#呼吸困难#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39633, encryptionId=21753963364, topicName=呼吸困难)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512606, encodeId=3dbf1512606d1, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300734, encodeId=5e00300e34a5, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Mar 29 06:57:44 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300642, encodeId=14e73006425c, content=药物并发症.禁忌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:34 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300641, encodeId=3b72300641cb, content=药物并发症, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:21 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-30 changjiu

    学习一下谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=307067, encodeId=ea8b30e06741, content=还有这样的副作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/10/4591d13f0d10510467d5b87f98bc17f8.jpg, createdBy=aad42328838, createdName=成长中, createdTime=Wed Apr 18 23:31:41 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301254, encodeId=96e03012548f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 30 20:22:18 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281862, encodeId=d1311281862ec, content=<a href='/topic/show?id=21753963364' target=_blank style='color:#2F92EE;'>#呼吸困难#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39633, encryptionId=21753963364, topicName=呼吸困难)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512606, encodeId=3dbf1512606d1, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300734, encodeId=5e00300e34a5, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Mar 29 06:57:44 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300642, encodeId=14e73006425c, content=药物并发症.禁忌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:34 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300641, encodeId=3b72300641cb, content=药物并发症, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:21 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=307067, encodeId=ea8b30e06741, content=还有这样的副作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/10/4591d13f0d10510467d5b87f98bc17f8.jpg, createdBy=aad42328838, createdName=成长中, createdTime=Wed Apr 18 23:31:41 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301254, encodeId=96e03012548f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 30 20:22:18 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281862, encodeId=d1311281862ec, content=<a href='/topic/show?id=21753963364' target=_blank style='color:#2F92EE;'>#呼吸困难#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39633, encryptionId=21753963364, topicName=呼吸困难)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512606, encodeId=3dbf1512606d1, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300734, encodeId=5e00300e34a5, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Mar 29 06:57:44 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300642, encodeId=14e73006425c, content=药物并发症.禁忌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:34 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300641, encodeId=3b72300641cb, content=药物并发症, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:21 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-30 丁鹏鹏
  5. [GetPortalCommentsPageByObjectIdResponse(id=307067, encodeId=ea8b30e06741, content=还有这样的副作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/10/4591d13f0d10510467d5b87f98bc17f8.jpg, createdBy=aad42328838, createdName=成长中, createdTime=Wed Apr 18 23:31:41 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301254, encodeId=96e03012548f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 30 20:22:18 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281862, encodeId=d1311281862ec, content=<a href='/topic/show?id=21753963364' target=_blank style='color:#2F92EE;'>#呼吸困难#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39633, encryptionId=21753963364, topicName=呼吸困难)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512606, encodeId=3dbf1512606d1, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300734, encodeId=5e00300e34a5, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Mar 29 06:57:44 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300642, encodeId=14e73006425c, content=药物并发症.禁忌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:34 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300641, encodeId=3b72300641cb, content=药物并发症, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:21 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-29 飛歌

    厉害了我的哥

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=307067, encodeId=ea8b30e06741, content=还有这样的副作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/10/4591d13f0d10510467d5b87f98bc17f8.jpg, createdBy=aad42328838, createdName=成长中, createdTime=Wed Apr 18 23:31:41 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301254, encodeId=96e03012548f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 30 20:22:18 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281862, encodeId=d1311281862ec, content=<a href='/topic/show?id=21753963364' target=_blank style='color:#2F92EE;'>#呼吸困难#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39633, encryptionId=21753963364, topicName=呼吸困难)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512606, encodeId=3dbf1512606d1, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300734, encodeId=5e00300e34a5, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Mar 29 06:57:44 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300642, encodeId=14e73006425c, content=药物并发症.禁忌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:34 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300641, encodeId=3b72300641cb, content=药物并发症, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:21 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-29 张新亮1853311252142e2fm

    药物并发症.禁忌症

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=307067, encodeId=ea8b30e06741, content=还有这样的副作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/10/4591d13f0d10510467d5b87f98bc17f8.jpg, createdBy=aad42328838, createdName=成长中, createdTime=Wed Apr 18 23:31:41 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301254, encodeId=96e03012548f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 30 20:22:18 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281862, encodeId=d1311281862ec, content=<a href='/topic/show?id=21753963364' target=_blank style='color:#2F92EE;'>#呼吸困难#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39633, encryptionId=21753963364, topicName=呼吸困难)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512606, encodeId=3dbf1512606d1, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Mar 30 13:49:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300734, encodeId=5e00300e34a5, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Thu Mar 29 06:57:44 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300642, encodeId=14e73006425c, content=药物并发症.禁忌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:34 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300641, encodeId=3b72300641cb, content=药物并发症, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu Mar 29 00:22:21 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-29 张新亮1853311252142e2fm

    药物并发症

    0

相关资讯

小咳嗽,大问题,任何蛛丝马迹万万不可忽略!

心力衰竭是绝大多数心血管疾病的最终“归宿”,虽然随着医学的不断发展,心血管疾病的死亡率有所下降,但心力衰竭的发生率却一直处于一个比较高的水平。

咳嗽、喘息别惯性思维 小心忽略这个病

气管、支气管异物为耳鼻咽喉科常见急危疾病之一,多见于5岁以下儿童,严重性取决于异物的性质和造成气道阻塞的程度,轻者可致肺部损害,重者可窒息死亡。80%发生于儿童,3岁以下儿童占65%。

NEJM:马尔尼菲踝节菌-病例报道

马尔尼菲踝节菌是一种二相性真菌,在华南、东南亚和印度东北部等地区流行,引起居住在这些地区的HIV感染者发生感染。马尔尼菲踝节菌感染的发生率随着与高活性抗逆转录病毒疗法使用增加而有所降低。然而,现在马尔尼菲踝节菌感染的发病率在其它细胞介导的免疫功能受损的患者中越来越高,比如那些接受过器官移植的患者。

病例分享:咳嗽2月抗生素治不好,精检查细分析发现罕见妖孽!

2017年1月初着凉后出现咳嗽伴少量白粘痰,无发热、气促等不适。因原有哮喘史,故予舒利迭、普米克都保治疗,但无缓解,遂于1月中旬至当地医院予左氧氟沙星0.5g qd+甲强龙 40mg qd静滴,4天后症状好转。停药3天后再次出现咳嗽咳痰,予莫西沙星0.4g qd+ 甲强龙 40mg qd静滴,5天后好转。

2017 CHEST指南:结核病和其他慢性感染引起的咳嗽

咳嗽是肺结核和其他慢性呼吸道感染的常见症状,本文是对2006年ACCP指南关于结核病和其他慢性感染引起的咳嗽章节的更新,主要目的是确定肺结核咳嗽患者检测的最佳时间和诊断策略。全文共提出了8个关键问题,并针对这些关键问题提出建议。

寻寻觅觅已8年为了一个菌,基因测序拨迷雾治好一种病!

泌尿系统感染(UTIs)是导致小婴儿(≤60天)住院的常见原因之一。美国每年有超过20,000名一岁以内的患儿因泌尿系感染入院。尽管肠外用抗生素经常作为治疗≤60天婴儿侵袭性细菌感染的首要选择之一,但是关于婴儿泌尿系统感染抗生素静脉治疗的最佳疗程尚无定论,因而实际治疗中存在差异。